Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Breast 3Genitourinary 2Gastrointestinal 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 17fludarabine phosphate 14Whole-Body Irradiation 11Mycophenolic Acid 9Epoetin Alfa 9Cyclosporine 9Busulfan 9fludarabine 8Cord Blood Stem Cell Transplantation 8Antilymphocyte Serum 8Filgrastim 6Tacrolimus 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5Methotrexate 5Darbepoetin alfa 5Dalteparin 5Cytarabine 5eltrombopag 4Tinzaparin 4Thiotepa 4Platelet Transfusion 4Melphalan 4Etoposide 4Arsenic Trioxide 4thymoglobulin 3epoetin beta 3Vorinostat 3Transplantation 3Methylprednisolone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × lonafarnib × Classical hematology × Clear all
NCT00109538 2015-05-01

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 3 Terminated
47 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡